RECORD // Company

Zymeworks Inc.

Formerly: Zymeworks Delaware Inc.

Built 2026-11-21T11:37:24Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (2 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

Gleif lei (1)
  • Zymeworks Inc. · legal entity in this company's GLEIF ownership tree (LEI 894500AHOYAGYLYZJL67)
SEC EDGAR (1)
Matched by name only, not merged (1)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • ZYMEWORKS INC. · East licences · same registered legal name as 'Zymeworks Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare

6 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-09 · accession 0001937653-26-000068

ItemValuePeriodFormFiledAccessionReport
Revenue$256,460,0003 months ended 2026-09-3010-Q2026-11-090001937653-26-0000682026-11-21 11:37 UTCReport an error
Net income (loss)$173,700,0003 months ended 2026-09-3010-Q2026-11-090001937653-26-0000682026-11-21 11:37 UTCReport an error
Interest expense$591,0009 months ended 2026-09-3010-Q2026-11-090001937653-26-0000682026-11-21 11:37 UTCReport an error
Cash and cash equivalents$100,464,000at 2026-09-3010-Q2026-11-090001937653-26-0000682026-11-21 11:37 UTCReport an error
Contract liabilities, current$16,659,000at 2026-09-3010-Q2026-11-090001937653-26-0000682026-11-21 11:37 UTCReport an error
Contract liabilities, noncurrent$0at 2026-09-3010-Q2026-11-090001937653-26-0000682026-11-21 11:37 UTCReport an error

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001937653
Ticker
ZYME
EIN
883099146
CUSIP
98985Y108
Record ID
sx:sec:0001937653

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

35 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-18SEC EDGAR company profile2026-11-21 11:37 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-18SEC EDGAR company profile2026-11-21 11:37 UTCReport an error
State of incorporationDE2026-11-18SEC EDGAR company profile2026-11-21 11:37 UTCReport an error
Fiscal year end (MMDD)12312026-11-18SEC EDGAR company profile2026-11-21 11:37 UTCReport an error
Business address108 PATRIOT DRIVE, SUITE A, MIDDLETOWN, DE, 197092026-11-18SEC EDGAR company profile2026-11-21 11:37 UTCReport an error
ExchangesNasdaq2026-11-18SEC EDGAR company profile2026-11-21 11:37 UTCReport an error
Revenue (fiscal year ended 2025-12-31)$105,965,0002025-12-3110-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax2026-11-21 11:37 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-81,130,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-21 11:37 UTCReport an error
Total assets (at 2025-12-31)$346,527,0002025-12-3110-K, XBRL Assets2026-11-21 11:37 UTCReport an error
Stockholders' equity (at 2025-12-31)$268,501,0002025-12-3110-K, XBRL StockholdersEquity2026-11-21 11:37 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$41,157,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-21 11:37 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-33,005,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-21 11:37 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$1,521,0002025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-21 11:37 UTCReport an error
Operating lease liabilities (at 2025-12-31)$18,267,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-21 11:37 UTCReport an error
Form D total offering amount (D filed 2024-01-03)$50,000,5022024-01-03D2026-11-21 11:37 UTCReport an error
Form D total amount sold (D filed 2024-01-03)$49,999,9932024-01-03D2026-11-21 11:37 UTCReport an error
Form D industry groupBiotechnology2024-01-03D2026-11-21 11:37 UTCReport an error
Form D revenue rangeDecline to Disclose2024-01-03D2026-11-21 11:37 UTCReport an error
Form D date of first sale2023-12-282024-01-03D2026-11-21 11:37 UTCReport an error
8-K Item 8.01, OTHER EVENTS (filed 2026-11-16)On November 16, 2026, Zymeworks Inc. (the “Company”) issued a press release announcing that its Board of Directors had authorized a second 2026 share repurchase program (the “Second 2026 Share Repurchase Program”) under which the Company may repurchase up to $200.0 million of its outstanding common stock, par value $0.00001 per share, through 2028. The Company has completed its initial 2026 share repurchase program under which the Company was authorized to repurchase up to $125.0 million of its outstanding common stock.2026-11-16SEC EDGAR 8-K 0001937653-26-000070 (text as filed, excerpt)2026-11-21 11:37 UTCReport an error
8-K Item 7.01, REGULATION FD DISCLOSURE (filed 2026-11-16)On November 16, 2026, the Company issued a press release regarding the Second 2026 Share Repurchase Program. A copy of this press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference. The information set forth in this Item 7.01 and in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.2026-11-16SEC EDGAR 8-K 0001937653-26-000070 (text as filed, excerpt)2026-11-21 11:37 UTCReport an error
8-K Item 2.02, RESULTS OF OPERATIONS AND FINANCIAL CONDITION (filed 2026-11-09)On November 9, 2026, Zymeworks Inc. (the “Company”) issued a press release announcing its financial results for the three months ended September 30, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K (this “Form 8-K”).2026-11-09SEC EDGAR 8-K 0001937653-26-000067 (text as filed, excerpt)2026-11-21 11:37 UTCReport an error
8-K Item 7.01, REGULATION FD DISCLOSURES (filed 2026-11-09)The Company announces material information to the public through a variety of means, including filings with the Securities and Exchange Commission, press releases, public conference calls, the Company’s website (www.zymeworks.com), its investor relations website (ir.zymeworks.com), its news site (ir.zymeworks.com/press-releases), its publications site (zymeworks.com/publications) and its events and presentations site (ir.zymeworks.com/events-and-presentations). The Company uses these channels, as well as social media, including its X account (@ZymeworksInc) and LinkedIn account (www.linkedin.com/company/zymeworks), to communicate with investors and the public about the Company, its product…2026-11-09SEC EDGAR 8-K 0001937653-26-000067 (text as filed, excerpt)2026-11-21 11:37 UTCReport an error
8-K Item 1.01, ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT (filed 2026-10-23)On October 22, 2026, Zymeworks Inc. and its subsidiary Zymeworks BC Inc. (together, the “Company”) entered into a Collaboration and License Agreement (the “Collaboration and License Agreement”) with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, “Roche”), granting Roche exclusive rights to develop and commercialize the Company’s proprietary trispecific T-cell engager targeting DLL3-expressing tumor cells product candidate known as ZW209 (“ZW209”) throughout the world. License. Under the terms of the Collaboration and License Agreement, the Company granted to Roche an exclusive, worldwide, royalty-bearing license, with the right to grant sublicenses, under certain of the…2026-10-23SEC EDGAR 8-K 0001937653-26-000055 (text as filed, excerpt)2026-11-21 11:37 UTCReport an error
8-K Item 7.01, REGULATION FD DISCLOSURE (filed 2026-10-23)On October 23, 2026, Zymeworks Inc. issued a press release regarding the Collaboration and License Agreement. A copy of this press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference. The information set forth in this Item 7.01 and in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.2026-10-23SEC EDGAR 8-K 0001937653-26-000055 (text as filed, excerpt)2026-11-21 11:37 UTCReport an error
Largest institutional holder #1 (13F as filed): EcoR1 Capital, LLC$600,445,9422026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:37 UTCReport an error
Largest institutional holder #2 (13F as filed): Rubric Capital Management LP$182,980,0002026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:37 UTCReport an error
Largest institutional holder #3 (13F as filed): BlackRock, Inc.$111,121,9252026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:37 UTCReport an error
Largest institutional holder #4 (13F as filed): PERCEPTIVE ADVISORS LLC$109,342,3912026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:37 UTCReport an error
Largest institutional holder #5 (13F as filed): BVF INC/IL$95,388,5722026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:37 UTCReport an error
Largest institutional holder #6 (13F as filed): Assenagon Asset Management S.A.$65,455,9722026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:37 UTCReport an error
Largest institutional holder #7 (13F as filed): BNP PARIBAS ASSET MANAGEMENT Holding S.A.$46,558,3732026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:37 UTCReport an error
Largest institutional holder #8 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$40,752,2082026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:37 UTCReport an error
Largest institutional holder #9 (13F as filed): Nextech Invest Ltd.$29,118,5482026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:37 UTCReport an error
Largest institutional holder #10 (13F as filed): STATE STREET CORP$28,445,9662026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:37 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.